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Introduction Vaccination is an effective preventive strategy against
influenza. However, current trivalent influenza vaccines (TIVs)
contain only one of the two influenza B lineages that circulate each
year. Vaccine mismatches are frequent because predicting which one
will predominate is difficult. Recently licensed quadrivalent
influenza vaccines (QIVs) containing the two B lineages should
address this issue. Our study estimates their impact by assessing
what would have been the US public health benefit of routinely
vaccinating with QIV in 2000–2013.
Methods We developed a dynamic compartmental model that
accounts for interactions between influenza B lineages (natural or
vaccine-induced) and simulates the multiyear influenza dynamics
for 2000–2013. Age-structured population dynamics, vaccine
efficacy (VE) per strain, and weekly ramp-up of vaccination
coverage are modeled. Sensitivity analyses were performed on VE,
duration of immunity, and levels of vaccine-induced cross-
protection between B lineages.
Results Assuming a cross-protection of 70% of the VE of the
matched vaccine, the model predicts 16% more B lineage cases
prevented by QIV. Elderly (≥65 years) and young seniors (50–
64 years) benefit most from QIV, with 21% and 18% reductions in
B lineage cases. Reducing cross-protection to 50%, 30%, and 0% of
the VE of the matched vaccine improves the relative benefit of QIV
to 25%, 30%, and 34% less B lineage cases.
Conclusion Using a dynamic retrospective framework with real-life
vaccine mismatch, our analysis shows that QIV routine vaccination
in the United States has the potential to substantially reduce the
number of influenza infections, even with relatively high estimates
of TIV-induced cross-protection.
Keywords Dynamic model, influenza, quadrivalent influenza vac-
cine, trivalent influenza vaccine, vaccine effectiveness, vaccines.
Please cite this paper as: Crepey et al. (2015) Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza and Other
Respiratory Viruses 9(Suppl. S1), 39–46.
Introduction
Controlling seasonal influenza epidemics is a challenge for
public health authorities worldwide. Although vaccination has
proved to be an effective strategy, the vaccine antigenic
composition frequently does not match the circulating virus
strains. Two influenza A subtypes (A/H1N1 and A/H3N2) and
two influenza B lineages (B/Victoria and B/Yamagata) have
been circulating in the United States and worldwide, whereas
commercialized influenza vaccines are trivalent and include
the two A subtypes but only one B lineage (either B/Victoria or
B/Yamagata). Every year, the World Health Organization
(WHO) issues recommendations on the composition of the
next influenza vaccine based on analyses from its network of
corresponding centers. But, past experiences have shown that
those recommendations do not always correspond to influ-
enza virus circulation of the following epidemic season.1 The
resulting mismatched vaccine has an efficacy lower than
expected and fails to prevent a significant proportion of
influenza infection.2 New quadrivalent influenza vaccines
(QIV) that contain both circulating B lineages have been
approved for use in the United States since 2012. Their
demonstrated efficacy in children and adults has the potential
to overcome the drawbacks of wrongly predicting which B
lineage will predominate in a given year.3–5 Quadrivalent
influenza vaccines are expected to provide a significant public
health and economic benefit, as shown by recent studies.6–9
However, none of these studies considered the dynamic nature
of influenza infection. In addition, they did not assess the
impact of introducing a new vaccine strain on the evolution of
the population immunity status and its implications on the
long-term dynamics of seasonal influenza epidemics. Another
key factor in QIV evaluation, often overlooked, is the potential
cross-protection against a mismatched B lineage conferred by
the trivalent influenza vaccines (TIV), obviously limiting the
added value of QIV over TIV.
The aim of our analysis was to retrospectively assess what




ª 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. 39
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
the United States during the period 2000–2013, taking into
account the transmissible nature of influenza as well as
multiyear immunity acquired by infection and interaction
between B lineages due to natural or vaccine-induced cross-
protection. Due to the comparative nature of our study, we
mainly report differences on influenza B cases, but do show
estimates and results for influenza A to provide the full
perspective and enhance comparisons.
Methods
Influenza incidence
Circulation of strains in the United States is reported in the
weekly influenza activity reports from the US Centers for
Disease Control and Prevention (CDC). We used these data
for the study period of interest from 2000 to 2013 (Table 1),
along with the influenza B lineage contained in the TIV
vaccine used for a given year. To obtain weekly time series of
influenza incidence by age and for each A subtype (H1N1,
H3N2) and B lineage, we used the weekly age distribution of
visits for influenza-like illness from the CDC’s US Outpatient
Influenza-like Illness Surveillance Network (ILINet), applied
to the WHO Collaborating Laboratories and the CDC’s
National Respiratory and Enteric Virus Surveillance System
(WHO/NREVSS) data regarding the proportions of influ-
enza-positive tests. In doing so, we are making the assump-
tions that most tested patients had influenza-like symptoms.
We then applied the yearly strains distribution published by
the CDC to each age group’s time series of influenza cases.
Vaccine uptake and efficacy
Our analysis uses weekly age-based vaccination coverage
from the CDC’s Behavioral Risk Factor Surveillance System
and National Immunization Survey. We collected weekly
influenza vaccination uptakes over the period 2000–2013
from CDC and collected separately vaccine efficacy (VE) by
strain2 and by age (CDC, unpublished data). We then
combined the two datasets, assuming the same relative
efficacy by age between different strains (Table 2). VE is
considered to be against infection.
Cross-protection
We only consider in our model cross-protection between B
lineage, because any potential heterosubtypic immunity
between A/H1N1 and A/H3N2 would not impact the
comparison between TIV and QIV. A recent review by
DiazGranados et al.2 gives a VE point estimate of 71% against
a matched strain and 49% against a non-matched B strain. In
our model, we used the same ratio of decreased efficacy (49/
71 = 70%of VE) to estimate themismatched efficacy or cross-
protection. To analyze its impact on our results, we varied this
estimate from 75% to 0%, with intermediate steps.
Our assumption is in line with another study that assumed
66% of the matching VE,8 and conservative compared with
another study that does not consider cross-protection at all.6
Following results from DiazGranados et al.,2 we assumed no
loss of efficacy if the mismatch was on the strain but not on
the subtype for A and lineage for B. The other main model
inputs are given in Table 2.
Epidemiological model
The model is structured in nine age groups: 0–6 months, 6–
23 months, 2–4 years, 5–10 years, 11–14 years, 15–18 years,
19–49 years, 50–64 years, and ≥65 years. It is composed of
two submodels that independently capture influenza A- and
influenza B-type epidemics. The model for influenza A
Table 1. Influenza strain circulation among cases
Season






% of A among
all cases H1N1 (%) H3N2 (%)
B strain
in vaccine
2000–2001 46 100 0 536 97 3 Yamagata
2001–2002 13 23 77 875 2 98 Yamagata
2002–2003 43 040 996 574 75 25 Victoria
2003–2004 1 93 7 990 0 100 Victoria
2004–2005 25 74 26 754 0 100 Yamagata
2005–2006 19 22 78 809 8 92 Yamagata
2006–2007 21 23 77 792 62 38 Victoria
2007–2008 29 98 2 710 26 74 Victoria
2008–2009 34 17 83 665 89 11 Yamagata
2009–2010 1 12 88 990 95 5 Victoria
2010–2011 26 6 94 740 38 62 Victoria
2011–2012 18 48 52 820 25 75 Victoria
2012–2013 30 64 36 70 6 94 Yamagata
Source: US Centers for Disease Control and Prevention, weekly influenza activity. http://www.cdc.gov/flu/weekly.
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(Figure S1) is a variation of a compartmental SEIR model,
where individuals can be either susceptible to infection (S),
exposed but not infectious (E), infectious (I), or have
acquired an immunity to the disease (recovered; R). In
addition, we have added a vaccination compartment (V) to
account for individuals effectively protected from infection
by vaccination. To account for possible independent infec-
tion by influenza A/H1N1 and influenza A/H3N2, we have
split the E, I, and R compartments. As both TIV and QIV
systematically contain antigens of the two subtypes, it was
not necessary to split the V compartment.
The model for influenza B, shown in Figure 1, is built on
the same initial principle as the model for influenza A.
However, while no interaction is documented between A/
H1N1 and A/H3N2, several studies have shown that both
vaccine-induced and naturally acquired protection against a
B lineage occur when a person is vaccinated against or
infected by the other.2,10 The model accounts for such
interactions by considering a second sequence of infection
after each primary infection. Once individuals have been
infected by one lineage, they shift to the R compartment
corresponding to their infection. Then, they may be infected
by the other lineage, but with a lower probability corre-
sponding to the natural cross-protection they acquired with
the primary infection. For vaccine-induced cross-protection,
the process is similar: individuals protected against one
lineage can be infected, with a lower probability, by the other
lineage. In both cases, individuals will end up in a
compartment where they will be immune to both kinds of
infection for the duration of their naturally acquired
immunity.
Both submodels are age-structured, with nine age groups
(0–6 months, 6–23 months, 2–4 years, 5–10 years, 11–
14 years, 15–18 years, 19–49 years, 50–64 years, and
≥65 years) and use a contact matrix to account for the
heterogeneity of contacts between age groups. Due to the
absence of published contact data in the United States,
mainly available for European countries,11 we used mean
daily time of exposure between age groups in the United
States compiled by Zagheni et al.12 Equations of the model
are given as supplementary material.
Calibration process
Probabilities of influenza infection – bv and by, respectively –
for B/Victoria and B/Yamagata are calibrated simultaneously.
In addition, to replicate yearly variations in influenza peaks
and dominance of one lineage over the other, we first
calibrate bvi and byi for the first year i = 2000. The final state
of year i is the initial state of year i + 1. We then calibrate
bvi + 1 and byi + 1 for year i + 1, taking into account the
population immune status acquired the previous years. Each
year, the population is vaccinated with a TIV containing the
B lineage which was used that year. We use a 10-year ‘burn-
in’ period (between 1990 and 2000), with the same epidemic
parameters, to let the model reach steady initial values for the
first year of calibration (year 2000). We end up with a set of
(bvi, byi), containing one b per lineage and per year, each
accounting for variations that could not be explained by the
evolution of the population immunity (either vaccine or
infection induced), but potentially by external factors
(climate, strain pathogenicity, etc.).
In contrast to other approaches, mainly in static models,
consisting of the computation of an expected probability of
infection without vaccination,6 this process directly allows us
to account for the impact of vaccination, as the estimates are
computed under a given coverage, vaccine composition, and
efficacy; TIV, in this case. The calibration uses a Nelder–
Mead simplex algorithm13 with a least square fitness
function. The model and calibration process are imple-
mented in R14 and take approximately 4 hours to compute
on a 26 GHz microprocessing core.
Table 2. Model parameters
Parameters Base case Range Sources
Duration of latent period 1 day N/A Carrat et al.16
Duration of viral shedding 48 days N/A Carrat et al.16
Proportion of symptomatic
infection











































CDC, US Centers for Disease Control and Prevention; VE, vaccine
efficacy.
*With exponential decay.
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Figure 2 shows the match obtained, after calibration,
between weekly incidence time series computed by the model
and weekly incidence observed over the period 2000–2013.
Our calibration process allowed the model to achieve R2 of
954% and 930% for B/Victoria and B/Yamagata, respec-
tively. Ranges of R0 yearly variations, classically computed
15
with beta estimated by the model, are given in Table 2 for B/
Victoria, B/Yamagata, and for A/H1N1 and A/H3N2 (the
absence of epidemic circulation of a particular strain in a
given year yields an R0 < 1, which is not shown in the table).
Scenarios and sensitivity analyses
Our analysis is focused on the assessment of the potential
incremental differences of using QIV instead of TIV.
Consequently, we systematically compare a TIV scenario
with a QIV scenario regarding the number of cases due to
influenza B strains. Because yearly incidences depend on the
incidence of previous years, each yearly impact of a vaccine
cannot be interpreted independently. Consequently, we
could not easily estimate a confidence interval of ‘yearly
vaccine impact’, and computed instead an impact range
defined as the minimum and maximum of the moving
average of the vaccine impact with window of 5 years.
Cross-protection plays a crucial role in the estimation of
the benefits of a multistrain vaccine. We conservatively used
a relatively high estimate of cross-protection as our base case,
but chose to vary this estimate in a sensitivity analysis where
values go from 0% to 75% of the VE against the matched
strain.
For each scenario, the probabilities of infection were
recalibrated using the process described earlier, as every
change in cross-protection, duration of immunity, and
vaccine effectiveness affects the dynamics of the epidemic
and hence the potential effects of the vaccine. We did not
define a dedicated sensitivity analysis on vaccine coverage;
however, by design, coverage and efficacy play a similar role
at the population level of our model. Consequently, the
results we show on the sensitivity to efficacy variations can be
directly interpreted as results on the sensitivity to coverage
variations for a fixed efficacy.
Results
Assuming a cross-protection of 70% of the VE of a matching
vaccine, the model predicts that QIV would have prevented
on average 1580% (1037%; 227%) (min–max, moving
average over 5 years) extra B lineage cases than TIV over the



























Figure 1. Diagram of the influenza B part of
the dynamic model. E, exposed but not
infectious; NXP, natural cross-protection; QIV,
quadrivalent influenza vaccine; R, acquired an
immunity to the disease (recovered); S,
susceptible to infection; V, vaccination
compartment; VXP, vaccine-induced cross-
protection.
2001 2003 20042002 2005 2006 2007 2008 2009 2010 2011 2012 2013
2001 2003 20042002 2005 2006 2007 2008 2009 2010 2011 2012 2013
B/Victoria weekly incidence (in cases/100 000 inhabitants)







Figure 2. Comparison of weekly influenza incidence for B/Victoria and B/
Yamagata predicted by the model versus the weekly incidence observed
over the period 2000–2013. Green lines indicate the observed incidence
and pink lines indicate the predicted incidence.
Crepey et al.
42 ª 2015 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
multiyear incidence evolution of B/Victoria and B/Yamagata
epidemics under TIV and QIV scenarios. The first point to
notice is the relatively large variations in cases prevented by
QIV, years with a mismatched TIV vaccine being mainly
years with the highest impact of QIV. It appears that over the
period 2000–2013, QIV would have prevented a cumulative
number of more than 62 million cases. Two other situations
can be highlighted. First, several years show a cocirculation of
the two lineages, which allows QIV to be beneficial even
during ‘vaccine match’ years. Second, with a QIV scenario,
some years display a slightly higher incidence for one B
lineage than a scenario with TIV alone. As shown in Table 3,
these correspond to years with TIV matching the circulating
B lineage (2006–2007, 2009–2011), and more importantly,
they follow a string of years combining TIV mismatch and
medium to high B circulation, leading to large numbers of
cases prevented by QIV (>16 million in 2004–2006 and
>27 million in 2007–2009). Concerning elderly individuals
(age ≥65 years) and young seniors (age 50–64 years),
Figure 4 shows that they benefit the most from QIV, with
21% and 18% reduction in B cases, respectively. Of note, the
infant population (age 0–6 months), not (yet) vaccinated,
benefits from QIV thanks to indirect protection of the other
age groups.
Sensitivity analyses
Figure 4 also shows that reducing the cross-protection








2005 2007 2009 2011 20132001 2003
B/Yamagata weekly incidence (in cases/100 000 inhabitants)
B/Victoria weekly incidence (in cases/100 000 inhabitants)
Figure 3. Base case comparison between trivalent influenza vaccine (TIV)
and quadrivalent influenza vaccine (QIV). Top panel shows influenza B/
Victoria weekly incidence time series. Bottom panel shows influenza B/
Yamagata weekly incidence time series. Pink lines indicate the TIV
scenario and green lines indicate the QIV scenario.
Table 3. Difference in influenza symptomatic cases of a routine vaccination with QIV compared with one TIV over the period 2000–2013. Negative
numbers indicate additional cases averted by QIV compared with TIV. The ‘relative difference with QIV’ columns give the relative difference between
QIV and TIV for cases and susceptible population. The last columns give the TIV B antigens matching, a match being defined as ‘the vaccine strain













(per 100 000) Cases
Susceptible
population
2000–2001 20 900 20 900 8 060 001 Match High
2001–2002 701 500 680 600 250 2060 019 Mismatch Medium
2002–2003 897 300 195 800 72 420 045 Match High
2003–2004 933 200 35 900 13 1560 048 Mismatch Low
2004–2005 1 876 100 942 900 340 1470 070 Match High
2005–2006 2 578 300 702 200 252 18 116 Mismatch Medium
2006–2007 2 565 700 12 600 4 080 127 Match Medium
2007–2008 5 108 700 2 543 000 901 3890 183 Mismatch High
2008–2009 5 311 400 202 700 71 670 270 Mismatch High
2009–2010 5 310 000 1400 0 160 244 Match Low
2010–2011 4 915 200 394 800 137 19 206 Match High
2011–2012 4 991 100 75 900 26 1480 171 Match Medium
2012–2013 6 267 800 1 276 700 438 34 190 Match High
Average 482 000 172 8/13 matches 7 high seasons
Total 6 267 800 2230 1580
QIV, quadrivalent influenza vaccine; TIV, trivalent influenza vaccine.
*Absolute number of cases are computed on a population without international migration.
Quadrivalent influenza vaccine impact in US
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the relative benefit of QIV to 25%, 30%, and 34% fewer B
cases in the United States for all age groups. In Figure 5, we
show the impact of varying VE across all age groups by
20% to +20%. Increasing VE tends to linearly increase the
relative benefits of QIV. In addition, in our model, VE and
vaccine coverage play a mutually exchangeable role at the
population level, which means that variations invaccination
coverage by 20% would display the same results. Hence, an
increase in vaccination coverage would also raise QIV-
relative benefits.
Lastly, we varied duration of immunity acquired by
infection from 6 to 18 years. Results displayed in Figure 6
show that an increased duration of acquired immunity tends
to decrease QIV impact. However, the relation seems to be
asymptotic; increasing the duration from 12 to 18 years only
reduces QIV impact by <1% (all age groups).
Our model is also able to simulate influenza A activity
(Figure S1). Although QIV have no additional impact on A
compared with TIV, it allows us to put QIV potential
benefits in the perspective of a global reduction in influenza
cases. Considering all influenza cases (A and B), our analysis
predicts a maximum reduction of 11% symptomatic cases on
year 2007–2008 and a total reduction on the entire 2000–
2013 time period of 32% of cases.
Discussion
The complex dynamic of communicable diseases should not
be underestimated when assessing preventive strategies. In
the case of influenza, vaccines have the potential to change
the dynamic of seasonal epidemics, mainly by changing the
balance between immunity acquired by infection and by
vaccination. Our results show that the benefit of QIV varies
from 1 year to another. Quadrivalent influenza vaccine
reduces the number of yearly cases during our study period
(2000–2013) by a low of 20 900 in 2000 to a high of
0%






































Figure 4. Cross-protection sensitivity analysis
showing reduction in B cases with quadrivalent
influenza vaccine (QIV) compared with trivalent
influenza vaccine (TIV) over the period 2000–
2013. The vertical line shows the base case
scenario.
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Figure 5. Vaccine efficacy sensitivity analysis.
QIV, quadrivalent influenza vaccine; TIV,
trivalent influenza vaccine.
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2 543 000 cases in 2007. For some specific epidemic contexts
of TIV matching the circulating B lineage and large QIV-
induced reductions in cases preceding years, the total
number of B cases can be larger with QIV than with TIV
(1400–394 800 more cases). However, this increase is just a
balancing effect due to even larger reductions in the number
of cases during previous years. The reduction in the number
of infections results in an increased number of individuals
susceptible to new infection the following seasons (up to
27%, or approximately 4 million). This effect does not
outweigh the public health benefit of QIV, as our model
predicts an average of 172 cases prevented annually per
100 000 inhabitants in the United States (or 482 000 fewer
cases per year). It also shows that the public health benefit of
QIV may have to be evaluated over several years, which may
reduce the economic effectiveness of the strategy due to the
discounting of future benefits.
In addition, we notice in Figures 4–6, displaying agewise
QIV-relative public health benefits, that young seniors and
the elderly benefited the most from the switch from TIV to
QIV. This result may be explained by the higher vaccination
coverage observed in those groups. Indeed, Figure 5 can be
interpreted as a sensitivity analysis on coverage and shows a
linear positive correlation between coverage (or efficacy) QIV
benefits. Hence, a higher coverage should allow QIV to
prevent even more influenza cases than would TIV.
Our study shares similar objectives and perspectives with
the analysis conducted by Reed et al.6 In addition to focusing
on the US population and sharing most of the data sources,
we simulated a hypothetical scenario where QIV would have
been used in place of TIV for the past years, and compared
the outcomes. This design allows us to assess under a realistic
epidemiologic context the impact of the two vaccines.
However, it limits our ability to describe potential long-
term impact of some hypothetical scenarios, like a long
duration of naturally acquired immunity (>12 years), but
projecting the use of QIV in the future would have required
additional assumptions about vaccine mismatch and B
lineage circulations, which may have impaired our results.
However, we also have fundamental differences: we used a
dynamic model, we considered cross-protection, differences
of VE, coverage, and contacts between age groups, and we
took into account the epidemiological link between influenza
seasons (population immunity of year N depends on year
N1). Hence, our results differ, as we show greater variations
of yearly benefits and a greater average number of avoided
cases (over the period 2001–2009, Reed et al. show 342 700
avoided cases by QIV, while we predict 661 600 for the same
period). However, both sets of results are correlated, as lows
and highs happen on the same years and remain around the
same order of magnitude over the whole time period
considered.
On the other hand, the study by Clements et al.,9 also set
in the United States, predicts that QIV would only prevent
on average 30 000 cases per year. This result corresponds in
our analysis to the 2003–2004 context of TIV mismatch and
low B circulation (Table 3). They use similar estimates of
incidence, VE, and cross-protection, but use a static model
and only perform a single-year analysis. Given the yearly
variations that we observe, and the correlations between
years, their results may not give a complete and accurate
estimate of the likely benefits of QIV over several years and
various epidemiological contexts.
Although we believe that our analysis is more advanced
than previous attempts, we must acknowledge some limits.
To keep the model understandable and manageable, we had
to make some simplifying assumptions. One of them
concerns individuals recently infected and naturally immune
against one strain, who may not be impacted by a vaccina-
tion with QIV, or with TIV containing the other strain.
Accounting for that situation would have implied tracking
too many combinations of remaining duration of immunity,
0%






































Figure 6. Sensitivity analysis of the duration of
immunity acquired upon infection. QIV,
quadrivalent influenza vaccine; TIV, trivalent
influenza vaccine.
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which was not feasible under the current design. In addition,
we considered that the simplification’s impact would be in
disfavor of vaccination, giving us more conservative results.
For the same reason, an infection by a strain, after
vaccination against the other one, leads to immunity against
the two strains for the duration of the naturally acquired
immunity. This simplification gives an advantage to TIV, as
it cannot happen with QIV, leading to more conservative
QIV-relative benefits. Finally, as we decided not to take into
account the growth of the population due to net immigra-
tion, we underestimate the real size of the population.
However, at the central year of our simulation (2007), our
population is 6% smaller than the census estimate. Conse-
quently, our average results may be underestimated by the
same amount.
As mentioned previously, QIV-relative benefits rise with
VE and coverage, meaning that the increased influenza
vaccine coverage in recent years, due to pediatric and
universal indications, is likely to favor QIV public health
impact in the future, but further studies are required to
confirm this effect. In addition, we considered that cross-
protection conferred by TIV does not vary with age; however,
no study demonstrates that this assumption is correct.
Conclusion
Using a realistic retrospective framework, with real-life vaccine
mismatch, our analysis shows that routine vaccination with
QIV has the potential to substantially reduce the number of
influenza infections. Although our base case scenario uses
relatively conservative estimates of TIV-induced cross-protec-
tion, it still shows a 1580%reduction in B cases over the period
considered. Our analysis highlights the necessity of taking
cross-protection into account and illustrates the potential
public health impact over several years due to the variety of
situations thatmay arise. Subsequent studies will have to assess
the economic value of the potential impact of QIV vaccine
strategies versus continuation of TIV.
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